DK3303384T3 - Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf - Google Patents

Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf Download PDF

Info

Publication number: DK3303384T3
Authority: DK; Denmark
Prior art keywords: binding molecules; neutralizing anti; influenza binding; influenza; neutralizing
Prior art date: 2015-06-01

Application number

DK16728534.5T

Other languages

English (en)

Inventor

Nicole Kallewaard-Lelay

Qing Zhu

Godfrey Jonah Rainey

Cuihua Gao

Srinath Kasturirangan

Changshou Gao

Original Assignee

Medimmune Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-01

Filing date

2016-05-31

Publication date

2021-10-18

2016-05-31 Application filed by Medimmune Llc filed Critical Medimmune Llc

2021-10-18 Application granted granted Critical

2021-10-18 Publication of DK3303384T3 publication Critical patent/DK3303384T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK16728534.5T 2015-06-01 2016-05-31 Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf DK3303384T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562169272P	2015-06-01	2015-06-01
PCT/US2016/035026 WO2016196470A1 (en)	2015-06-01	2016-05-31	Neutralizing anti-influenza binding molecules and uses thereof

Publications (1)

Publication Number	Publication Date
DK3303384T3 true DK3303384T3 (da)	2021-10-18

Family

ID=56118059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16728534.5T DK3303384T3 (da)	2015-06-01	2016-05-31	Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf

Country Status (21)

Country	Link
US (4)	US10442854B2 (da)
EP (2)	EP3960761A1 (da)
JP (3)	JP6867306B2 (da)
CN (2)	CN113480640B (da)
AU (2)	AU2016271323B2 (da)
BR (1)	BR112017025496A2 (da)
CA (1)	CA2987816C (da)
CY (1)	CY1125793T1 (da)
DK (1)	DK3303384T3 (da)
ES (1)	ES2894777T3 (da)
HR (1)	HRP20211510T1 (da)
HU (1)	HUE056407T2 (da)
LT (1)	LT3303384T (da)
MX (2)	MX389708B (da)
PL (1)	PL3303384T3 (da)
PT (1)	PT3303384T (da)
RS (1)	RS62446B1 (da)
RU (1)	RU2721706C2 (da)
SI (1)	SI3303384T1 (da)
SM (1)	SMT202100591T1 (da)
WO (1)	WO2016196470A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS60938B1 (sr) *	2013-10-02	2020-11-30	Medimmune Llc	Neutrališuća antitela na grip a i njihova upotreba
WO2016011035A2 (en)	2014-07-15	2016-01-21	Medlmmune, Llc	Neutralizing anti-influenza b antibodies and uses thereof
PT3303384T (pt) *	2015-06-01	2021-10-14	Medimmune Llc	Moléculas de ligação neutralizantes anti-influenza e suas utilizações
IL304940A (en)	2016-01-13	2023-10-01	Medimmune Llc	A method for treating type A influenza
US11780907B2 (en)	2018-01-26	2023-10-10	Regeneron Pharmaceuticals, Inc.	Human antibodies to influenza hemagglutinin
US20220298230A1 (en) *	2019-06-11	2022-09-22	The Rockefeller University	Antibodies and methods for treatment of viral infections
PH12022550963A1 (en) *	2019-10-28	2023-09-25	Regeneron Pharma	Anti-hemagglutinin antibodies and methods of use thereof
CN113121680B (zh) *	2021-04-12	2022-03-29	华南农业大学	一种抗h5亚型禽流感纳米抗体蛋白及其编码基因与应用
US20250243261A1 (en) *	2022-04-08	2025-07-31	Cz Biohub Sf, Llc	Antibody compositions and optimization methods
CN116874606B (zh) *	2023-09-08	2023-11-24	益科思特(北京)医药科技发展有限公司	一种靶向trop2和cd3的双特异性抗体及其制备方法与应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154600B (nl)	1971-02-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3766162A (en)	1971-08-24	1973-10-16	Hoffmann La Roche	Barbituric acid antigens and antibodies specific therefor
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4233402A (en)	1978-04-05	1980-11-11	Syva Company	Reagents and method employing channeling
JPS5896026A (ja)	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en)	1982-06-24	1989-10-18	NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD	Long-acting composition
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5981216A (en)	1985-04-01	1999-11-09	Alusuisse Holdings A.G.	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
ES2176484T3 (es)	1995-08-18	2002-12-01	Morphosys Ag	Bancos de proteinas/(poli)peptidos.
SE9504046D0 (sv)	1995-11-14	1995-11-14	Pharmacia Ab	Method of determining affinity and kinetic properties
DE69724249T2 (de)	1996-05-23	2004-06-09	Inverness Medical Switzerland Gmbh	Verbesserungen in oder in bezug auf spezifische bindungsassays
US6300104B1 (en)	1997-06-19	2001-10-09	The Regents Of The University Of California	Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
JP2002530081A (ja)	1998-11-18	2002-09-17	ジェネンテック・インコーポレーテッド	親抗体より高度な結合親和性を持つ抗体変異体
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en)	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
WO2000059932A1 (fr)	1999-03-31	2000-10-12	Otsuka Pharmaceutical Co., Ltd.	Peptides se liant a l'hemagglutinine du virus de la grippe
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
JP4656478B2 (ja)	2000-02-22	2011-03-23	株式会社医学生物学研究所	抗体ライブラリー
ATE309385T1 (de)	2000-06-28	2005-11-15	Glycofi Inc	Verfahren für die herstellung modifizierter glykoproteine
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
EP1551875A4 (en)	2002-06-21	2006-06-28	Biogen Idec Inc	TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
AU2003251809A1 (en)	2002-07-11	2004-02-02	The General Hospital Corporation	Polynucleotide and polypeptide fat metabolism regulators and uses thereof
WO2005007697A1 (ja)	2003-07-23	2005-01-27	Fujirebio Inc.	抗インフルエンザａ型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具
CN103446582A (zh)	2003-08-11	2013-12-18	财团法人阪大微生物病研究会	包含诱导粘膜免疫的佐剂的新型疫苗
DK2112162T3 (da)	2004-07-10	2015-02-23	Fox Chase Cancer Ct	Genetisk modificerede humane naturlige dræbercellelinjer
WO2006124269A2 (en)	2005-05-16	2006-11-23	Amgen Fremont Inc.	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EP1957530A2 (en)	2005-10-21	2008-08-20	Novartis AG	Human antibodies against il13 and therapeutic uses
NZ598048A (en)	2006-01-17	2013-05-31	Synthon Biopharmaceuticals Bv	Compositions and methods for humanization and optimization of n-glycans in plants
AU2007226856A1 (en)	2006-03-21	2007-09-27	Michael Rynkiewicz	Methods for humanizing antibodies and humanized antibodies made thereby
WO2007117577A2 (en)	2006-04-07	2007-10-18	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human il-18 receptor
US20080014205A1 (en)	2006-05-15	2008-01-17	Lawrence Horowitz	Neutralizing Antibodies to Influenza Viruses
EA017203B1 (ru)	2006-09-07	2012-10-30	Круселл Холланд Б.В.	Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
PL2069403T3 (pl)	2006-10-02	2015-08-31	Regeneron Pharma	Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4
JP5601836B2 (ja)	2006-11-08	2014-10-08	マクロジェニックスウエスト，インコーポレイテッド	Ｔｅｓ７およびｔｅｓ７に結合する抗体
NO347649B1 (no)	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en)	2007-01-04	2007-02-14	Humabs Llc	Human cytomegalovirus neutralising antibodies and use thereof
EP2125886A2 (en)	2007-03-13	2009-12-02	Humabs LLC	Antibodies against h5n1 strains of influenza a virus
EP1995309A1 (en)	2007-05-21	2008-11-26	Vivalis	Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it)	2008-03-17	2009-09-18	Pomona Biotechnologies Llc	Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it)	2008-05-27	2009-11-28	Pomona Biotechnologies Llc	Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US8871207B2 (en)	2008-07-25	2014-10-28	Humabs, LLC	Neutralizing anti-influenza A virus antibodies and uses thereof
RU2553325C2 (ru)	2008-07-25	2015-06-10	Институт Фо Ресёч Ин Биомедицин	Нейтрализующие антитела против вируса гриппа а и их использование
WO2010027818A2 (en)	2008-08-25	2010-03-11	Dana-Farber Cancer Institute, Inc.	Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
CA2742969A1 (en)	2008-11-07	2010-05-14	Fabrus Llc	Anti-dll4 antibodies and uses thereof
AU2011344126B2 (en)	2010-12-13	2016-11-10	The University Of Utah Research Foundation	Vaccine antigens that direct immunity to conserved epitopes
US8961978B2 (en)	2011-07-14	2015-02-24	Crucell Holland B.V.	Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
MX352338B (es)	2011-07-18	2017-11-17	Inst Res Biomedicine	Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
AU2012312529B2 (en)	2011-09-20	2018-01-04	Icahn School Of Medicine At Mount Sinai	Influenza virus vaccines and uses thereof
WO2013044203A2 (en)	2011-09-23	2013-03-28	THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES	Novel influenza hemagglutinin protein-based vaccines
CA2861515A1 (en)	2011-12-05	2013-06-13	Trellis Bioscience, Llc	Antibodies useful in passive influenza immunization
US8834881B2 (en) *	2012-03-08	2014-09-16	Crucell Holland B.V.	Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
BR112015010817A8 (pt)	2012-11-13	2018-01-23	Genentech Inc	anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
KR20140118682A (ko)	2013-03-29	2014-10-08	(주)셀트리온	2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) *	2013-08-05	2014-12-27	Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства"	Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
RS60938B1 (sr) *	2013-10-02	2020-11-30	Medimmune Llc	Neutrališuća antitela na grip a i njihova upotreba
WO2016011035A2 (en) *	2014-07-15	2016-01-21	Medlmmune, Llc	Neutralizing anti-influenza b antibodies and uses thereof
PT3303384T (pt) *	2015-06-01	2021-10-14	Medimmune Llc	Moléculas de ligação neutralizantes anti-influenza e suas utilizações
IL304940A (en)	2016-01-13	2023-10-01	Medimmune Llc	A method for treating type A influenza
CN109195629A (zh)	2016-02-24	2019-01-11	威特拉公司	流行性感冒抗体分子制剂

2016
- 2016-05-31 PT PT16728534T patent/PT3303384T/pt unknown
- 2016-05-31 ES ES16728534T patent/ES2894777T3/es active Active
- 2016-05-31 AU AU2016271323A patent/AU2016271323B2/en not_active Ceased
- 2016-05-31 PL PL16728534T patent/PL3303384T3/pl unknown
- 2016-05-31 WO PCT/US2016/035026 patent/WO2016196470A1/en not_active Ceased
- 2016-05-31 SM SM20210591T patent/SMT202100591T1/it unknown
- 2016-05-31 DK DK16728534.5T patent/DK3303384T3/da active
- 2016-05-31 EP EP21186517.5A patent/EP3960761A1/en active Pending
- 2016-05-31 CN CN202110755761.8A patent/CN113480640B/zh active Active
- 2016-05-31 HU HUE16728534A patent/HUE056407T2/hu unknown
- 2016-05-31 CA CA2987816A patent/CA2987816C/en active Active
- 2016-05-31 RU RU2017145094A patent/RU2721706C2/ru active
- 2016-05-31 US US15/577,799 patent/US10442854B2/en active Active
- 2016-05-31 LT LTEPPCT/US2016/035026T patent/LT3303384T/lt unknown
- 2016-05-31 EP EP16728534.5A patent/EP3303384B1/en active Active
- 2016-05-31 CN CN201680030393.8A patent/CN107667114B/zh active Active
- 2016-05-31 HR HRP20211510TT patent/HRP20211510T1/hr unknown
- 2016-05-31 JP JP2017561892A patent/JP6867306B2/ja active Active
- 2016-05-31 RS RS20211271A patent/RS62446B1/sr unknown
- 2016-05-31 MX MX2017015189A patent/MX389708B/es unknown
- 2016-05-31 BR BR112017025496-4A patent/BR112017025496A2/pt not_active Application Discontinuation
- 2016-05-31 SI SI201631344T patent/SI3303384T1/sl unknown
2017
- 2017-11-27 MX MX2022001220A patent/MX2022001220A/es unknown
2019
- 2019-09-04 US US16/560,040 patent/US10882897B2/en active Active
2020
- 2020-12-01 US US17/108,608 patent/US11524993B2/en active Active
2021
- 2021-04-08 JP JP2021065590A patent/JP2021112193A/ja active Pending
- 2021-10-21 CY CY20211100923T patent/CY1125793T1/el unknown
2022
- 2022-11-11 US US18/054,757 patent/US11926657B2/en active Active
- 2022-11-18 AU AU2022271473A patent/AU2022271473A1/en not_active Abandoned
2023
- 2023-03-22 JP JP2023045036A patent/JP2023078352A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP3303384A1 (en)	2018-04-11
HUE056407T2 (hu)	2022-02-28
CA2987816A1 (en)	2016-12-08
CA2987816C (en)	2024-02-20
CN113480640B (zh)	2024-07-30
US20230112916A1 (en)	2023-04-13
US20200109187A1 (en)	2020-04-09
CN113480640A (zh)	2021-10-08
RS62446B1 (sr)	2021-11-30
LT3303384T (lt)	2021-10-11
HRP20211510T1 (hr)	2021-12-24
US20180155413A1 (en)	2018-06-07
MX2017015189A (es)	2018-04-13
AU2016271323B2 (en)	2022-08-25
US20210079069A1 (en)	2021-03-18
US10882897B2 (en)	2021-01-05
JP2018518475A (ja)	2018-07-12
BR112017025496A2 (pt)	2018-08-07
PT3303384T (pt)	2021-10-14
US10442854B2 (en)	2019-10-15
MX389708B (es)	2025-03-20
JP2023078352A (ja)	2023-06-06
RU2721706C2 (ru)	2020-05-21
JP2021112193A (ja)	2021-08-05
CY1125793T1 (el)	2024-02-16
US11926657B2 (en)	2024-03-12
RU2017145094A (ru)	2019-07-09
CN107667114B (zh)	2021-07-02
HK1250725A1 (zh)	2019-01-11
HK1253092A1 (zh)	2019-06-06
WO2016196470A1 (en)	2016-12-08
JP6867306B2 (ja)	2021-04-28
ES2894777T3 (es)	2022-02-15
AU2022271473A1 (en)	2022-12-22
EP3303384B1 (en)	2021-08-25
US11524993B2 (en)	2022-12-13
EP3960761A1 (en)	2022-03-02
SI3303384T1 (sl)	2021-11-30
RU2017145094A3 (da)	2019-11-06
MX2022001220A (es)	2022-03-02
CN107667114A (zh)	2018-02-06
PL3303384T3 (pl)	2022-01-03
SMT202100591T1 (it)	2021-11-12
AU2016271323A1 (en)	2018-01-18

Publication	Publication Date	Title
IL256416B (en)	2021-12-01	Multispecific antigen-binding molecules and uses thereof
IL272463A (en)	2020-03-31	Nucleic acid molecules and uses thereof
DK3265575T3 (da)	2021-05-31	Cd20-bindende molekyler og anvendelser deraf
IL261942A (en)	2018-10-31	Bcma binding molecules and methods of use thereof
DK3380522T3 (da)	2024-01-22	Antistofmolekyler til april og anvendelser deraf
LT3456346T (lt)	2021-09-27	Pd-1 ir lag-3 surišančios molekulės ir jų panaudojimo būdai
IL253653B (en)	2021-10-31	Binding molecules directed against influenza hemagglutinin and uses thereof
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
DK3116909T3 (da)	2020-01-20	Antistofmolekyler til lag-3 og anvendelser deraf
DK3303379T3 (da)	2021-12-06	Tigit-bindende midler og anvendelser deraf
HUE054339T2 (hu)	2021-08-30	CD73-ra specifikus kötõmolekulák és alkalmazásaik
IL246921B (en)	2019-09-26	Binding proteins and methods of use thereof
DK3303384T3 (da)	2021-10-18	Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
DK3099172T3 (da)	2021-11-22	Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
DK3155024T3 (da)	2020-11-23	Opholdsstrukturer og relaterede fremgangsmåder
DK3218358T3 (da)	2021-08-30	Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3105250T3 (da)	2020-09-28	Multispecifikke iga-bindingsmolekyler
LT3374398T (lt)	2020-09-10	Asct2 atžvilgiu specifinės surišančios molekulės ir jų panaudojimai
DK3209773T3 (da)	2020-06-15	Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3242685T3 (da)	2022-07-25	Cxcr4-bindende molekyler
IL261653A (en)	2018-10-31	Ilt7 binding molecules and methods of using the same
DK3417058T3 (da)	2021-11-15	Sortase-modificerede molekyler og anvendelser deraf
DK3128997T3 (da)	2020-08-24	Bindingmolekyler specifikke for il-21 og anvendelser deraf
GB201503812D0 (en)	2015-04-22	Antibody molecules and uses thereof
DK3321279T3 (da)	2020-03-09	Exenatidmodificeringsmiddel og anvendelse deraf